Polyplus: Mario Philips

Polyplus-transfection SA, a biotech which supports the gene and cell therapy market by supplying transfection solutions, has named Mario Philips as its new Chief Executive Officer.

Philips succeeds Karsten Wilking, who will transition into a Strategic Advisor role.

Philips brings the company, which is headquartered in the French city of Strasbourg, more than 20 years of experience in the life science and bioprocessing sectors.

He comes to Polyplus from his role as CEO of French biotech company Polyneuros, a developer of kits for the diagnosis and treatment of neurodegenerative conditions including Parkinson’s disease and ALS.  He was also a Strategic Partner with ArchiMed; and previously served as Vice President and General Manager of Pall Biotech, where he led the rapid expansion of the group’s core bioprocessing capabilities.

Prior to Pall Biotech, Philips served as Senior Vice President and General Manager of ATMI Life Sciences, where he led the introduction of new products and service solutions for the Life Sciences industry including the iCELLis single-use bioreactor for gene therapy applications.  

Philips graduated from Groep T – Internationale Hogeschool Leuven in Belgium with a degree in Marketing, after earning a degree in Biochemistry Engineering from CTL in Gent (now Hogeschool Gent).